IN-VITRO ACTIVITY OF ITRACONAZOLE AGAINST FLUCONAZOLE-SUSCEPTIBLE ANDFLUCONAZOLE-RESISTANT CANDIDA-ALBICANS ISOLATES FROM ORAL CAVITIES OFPATIENTS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS

A broth macrodilution technique, which was performed by following the recommendations provided by the National Committee for Clinical Labora tory Standards (document M27-P), was applied to study the in vitro act ivity of itraconazole against fluconazole-susceptible and -resistant C andida albicans isolates from the oral cavities of 100 patients infect ed with human immunodeficiency virus. The in vitro data demonstrated t hat itraconazole had good activity against the tested isolates; for 90 % of all strains of C. albicans, MICs were 1 mu g/ml, and only one iso late was highly resistant to this triazole (MIC, >16 mu g/ml). However , the itraconazole MICs for the fluconazole-susceptible isolates were significantly lower than those for the fluconazole-resistant isolates; the MICs for 50 and 90% of the isolates tested were less than or equa l to 0.03 and 0.25 mu g/ml, respectively, for the fluconazole-suscepti ble isolates and 0.5 and 1 mu g/ml, respectively, for the fluconazole- resistant isolates (P = 0.00001). Our findings could be of clinical re levance because human immunodeficiency virus-infected patients who fai l fluconazole therapy for oral and/or esophageal candidiasis may requi re itraconazole at doses higher than those used in standard therapy.